Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?

**Background:** The growth factor Angiotensin-2 signals through Angiotensin receptor type 1 (AT1-R) in a broad range of cell types and tumours and through the type-2 receptor (AT2-R) in a more restricted group of cell types. Although numerous forms of cancer have been shown to overexpress AT1-R, expression of AT1-R and AT2-R by human renal clear-cell carcinoma (RCCC) is not well understood. In this study, the expression of both angiotensin receptors was quantified in a retrospective series of RCCC and correlated with prognostic factors.

**Methods:** Angiotensin receptor type 1 and AT2-R expressions were quantified on tumour tissues by immunohistochemistry (IHC), western blot and quantitative reverse transcriptase PCR (qRT–PCR). IHC results were correlated to Fuhrman’s grade and patient progression-free survival (PFS).

**Results:** A total of 84 RCCC were analysed. By IHC, AT1-R and AT2-R were expressed to a greater level in high-grade tumours (AT1-R: P < 0.001, AT2-R: P < 0.001). Univariate analysis showed a correlation between PFS and AT1-R or AT2-R expression (P = 0.001). By multivariate analysis, only AT2-R expression correlated with PFS (HR 1.021, P = 0.006) and cancer stage (P < 0.001). By western blot, AT1-R and AT1-R were also found to be overexpressed in higher Fuhrman’s grade (P < 0.001) and P = 0.001, respectively). By qRT–PCR, AT1-R but not AT2-R mRNA were downregulated (P = 0.001 and P = 0.118, respectively).

**Conclusion:** Our results show that AT1-R and AT2-R proteins are overexpressed in the most aggressive forms of RCCC and that AT2-R expression correlates with PFS. AT1-R or AT2-R blockage could, therefore, offer novel directions for anti-RCCC therapy.

**Keywords:** renal cell carcinoma; AT1-R; AT2-R; Angiotensin-2; prognostic factor
Angiotensin-2 receptors in renal carcinoma
T Dolley-Hitze et al

MATERIALS AND METHODS

This study was designed retrospectively by using the Rennes database for RCCC from 2002 to 2006 and by exploring expression of angiotensin-2 receptors by several methods. All patients undergoing nephrectomy for sporadic RCCC in Rennes are included in a clinical and histological database, after giving informed consent.

Tumours specimens

Immediately after macroscopic examination, small samples are collected from surgical specimens, frozen in liquid nitrogen and stored at −80°C for RNA and protein extraction. Tumour tissues were also preserved in 10% formalin and embedded in paraffin for immunostaining. For protein or RNA extractions, 5μm tissue sections were cut before and after the samples. Hematoxylin–eosin staining was performed on sections to confirm or revise the Fuhrman’s grade and only controlled samples were included. If necrosis, fibrosis or non-tumourous kidney tissue was above 10% of total tissue examined, the corresponding sample was excluded from analysis.

Pathological, histological and clinical data

In this study, TNM (Tumour, Node and Metastasis) score, tumour size and Fuhrman’s grade were extracted from Rennes database for RCCC. These data are routinely evaluated for each tumour. Fuhrman’s grade, a nuclear grading system, is based on nuclear size, shape and prominence of nucleoli. This score is determined in the most aggressive tumour area and represents one of the key determinants of RCCC-specific survival (Fuhrman et al, 1982). Several clinical data were also used such as gender, age, delay between surgery and progression or death and performance status at surgical time (ECOG scale (Eastern Cooperative Oncology Group) (Oken et al, 1982)).

Immunohistochemistry (IHC)

For immunostaining, a representative paraffin block with the highest Fuhrman’s grade was selected; 5μm-thick sections were cut from each block. Immunostaining was performed on formalin-fixed, paraffin-embedded tissues using the labelled-polymer method. Slides were dewaxed and rehydrated using xylol and ethanol, respectively, and transferred in hot citrate buffer 0.01mol/l and pH 6 (cooked in 100°C, 40min), left in the hot buffer for 20 additional minutes and transferred into PBS-T 0.1% buffer for 5 min. Endogenous peroxidase was quenched in 3% hydrogen peroxide for 10 min and slides were again transferred into PBS-Tween 0.1% buffer for 5 min. After pre-incubation with FCS (fetal calf serum) 10% for 20 min (for AT1-R), the slides were incubated with a dilution of 1:500 (in PBS-T 1% FCS) rabbit polyclonal anti AT1-R antibody (Santa-Cruz, NT, USA; sc-1173) and a dilution of 1:100 (in primary antibody-diluting buffer) goat polyclonal anti AT2-R Antibody (Santa-Cruz; K15, sc-48432) at room temperature for 2h. Control without primary antibody was always performed at the same time with PBS-T 1% SVF (AT1-R), and primary antibody-diluting buffer (AT2-R). Sections were rinsed in PBS-T and incubated with polyclonal rabbit anti-goat immunoglobulin (1:200 dilution-30 min) for AT2-R only, followed by incubation with HRP (horseradish peroxidase)-labelled polymer conjugated with secondary antibodies (Envision + Dual link system-HRP, DAKO). Diaminobenzidine was used as a chromogen in the presence of hydrogen peroxide. Hematoxylin was used as a counterstain. Study specimens were evaluated by a single uropathologist (NRL) (Microscope: olympus BX51, camera: olympus DP70). Immunostaining of AT1-R and AT2-R was expressed as the percentage of AT1-R/AT2-R-positive tumour cells by scoring at least 1000 cells.

Western blot analysis

Protein lysates were prepared by treating frozen tissues with RIPA (radio immuno precipitation assay) buffer (consisting of 50 mM Tris-HCL pH8, 150 mM NaCl, 0.1% SDS and 1% NP40, 0.5% Na deoxycholate, 1 mM DTT and 10 μg/ml protease inhibitors) at 4°C (30–60 min). Tissue lysates were then centrifugated at 13 000 g for 30 min and supernatants were harvested. Protein concentrations were determined by the Bradford method. A volume of 25 μg of protein (boiled at 95°C) were separated by 12.5% SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and transferred to a nitrocellulose membrane. Each membrane was blocked with phosphate buffer saline (PBS) containing 5% skim milk for 2h, and incubated at 4°C overnight with 1500 of AT1-R (Santa-Cruz; sc-1173) or 1:200 of AT2-R (Santa-Cruz; H 143, sc-9040). The membrane was subsequently incubated for 1h at room temperature with fluorescent-labeled secondary antibody (IRDye Tmm 800-dilution 1:5000) and analysed using infrared imaging system (Odyssey-Biosciences). β-Actin was used as loading and blotting controls and detected by anti-human β-actin (clone AC-15, Sigma, Lyon, France).

RNA (ribonucleic acid) purification and quantitative RT–PCR (reverse transcript PCR)

Total RNA was extracted from tissues with the Genelute Mammalian total RNA Miniprep (RTN-70 Sigma), and treated with DNase I to avoid genomic DNA contamination. The RNA product was quantified by absorbance at 260 nm. The integrity of RNA samples was controlled by analysis on bioanalyzer with RNA 6000 Nano assay Labship (Agilent Technologies, Santa Clara, CA, USA) and ratio integral number (RIN) was calculated. Only RNA with RIN > 8 were further processed and used for cDNA synthesis. A volume of 1 μg of total RNA was transcribed into cDNA using high capacity cDNA Archive kit (Applied Biosystems, Foster City, CA, USA).

Quantitative PCR was performed with the PCRq 7900 HT (Applied biosystems) using power SYBR Green PCR Master mix (Applied biosystems). The reaction mixture contained 5 μl of master mix, 0.3 μl of each primer (10 μM) and 2 μl cDNA (diluted 1:40) for a total reaction volume of 10 μl. Oligonucleotide primers were synthesised by Eurogentec (Angers, France). The sequences

© 2010 Cancer Research UK
British Journal of Cancer (2010) 103(11), 1698 – 1705
of these primers were as follows: (forward) 5'-ATG-ATT-CCA-GCG-CCT-GAC-3' and (reverse) 5'-GGT-CCA-GAC-GTC-CTG-TCA-CT-3' for AT1-R, (forward) 5'-GGT-TTG-ATT-ATG-CAT-GCG-CCT-TCA-CCT-3' and (reverse) 5'-GCC-CAT-AGA-GGA-GTA-GCC-GTC-3' for AT2-R, (forward) 5'-GGT-CCT-TTC-ACC-AGC-AAG-CG-CT-3' and (reverse) 5'-GCT-TTC-TTT-GGT-CAG-GCA-GTA-3' for HPRT. The programme was as follows: an initial step at 95°C for 10 min and then 40 cycles of 15 s and 60°C for 60 s. Regression curves were drawn for each sample, and its relative amount was calculated from the threshold with the instrument's software (SDS 2.0) according to the manufacturer's instructions. Relative expression levels of the target genes were normalised mean of an internal control gene, HPRT.

Statistical analysis

Progression-free survival was determined from the date of surgery to the date of cancer progression or the last follow-up. Non-parametric tests (Kruskal Wallis) were used to compare means and proportions. Estimates of the cumulative survival distributions were calculated according to the Kaplan–Meier method and log-rank tests were used to compare the differences between groups. A Cox proportional-hazard regression model was used to test the independent effects of clinical and pathological variables on survival. Graphical methods suggested that the proportional-hazards assumption was reasonable for all selected variables. A stepwise selection procedure was used to select the final optimal model. All P-values were two-sided and P<0.05 was considered to indicate significance. All analyses were conducted with the Statistical Package for the Social Sciences, version 16.0 (SPSS Inc., Chicago, IL, USA).

RESULTS

A total of 84 patients who underwent nephrectomy between 2002 and 2006 were included in our study. All protein and RNA extracts from frozen samples corresponding to IHC Fuhrman’s grade were selected for western blot and qRT–PCR experiments (n = 55). Paraffin sections were done on all samples.

In all, 50 men and 34 women were included, with a mean age of 63.7 ± 11.3 years. At the time of surgery, 56 patients were ECOG 0 and 28 ECOG 1; three tumours were Fuhrman’s grade 1 (3.5%), 32 grade 2 (37.6%), 26 grade 3 (30.9%) and 23 grade 4 (27.3%). A total of 22 patients (26.2%) had lymph node involvement. Median tumour size was 7.0 ± 4.10 cm. No patient received anti-angiogenic therapy or chemotherapy before surgery. Mean follow-up was 30 months (± 18 months).

For the statistical analysis grade 1 and 2 were combined because of low number of grade 1 tumours.

Immunohistochemistry

Localisation of AT1-R and AT2-R was described on tumour tissue and normal surrounding tissue (Figure 1). Angiotensin receptor type 1 stained all tubular cells, podocytes, epithelial cells of Bowman’s capsule and vascular smooth-muscle cells in the normal cortex. AT2-R cortical staining localised only on tubular cells. Tumour cells, as well as normal renal cells, exhibited cytoplasmic staining but not membrane or nuclear immunostaining.

A total of 82 tumours were stained for AT1-R (3 Fuhrman’s grade 1, 31 grade 2, 26 grade 3 and 22 grade 4) and 76 for AT2-R (3 Fuhrman’s grade 1, 30 Fuhrman’s grade 2, 24 Fuhrman’s grade 3 and 19 Fuhrman’s grade 4). For each sample, the ratio of positive tumour cells/total tumour cells was expressed as a percentage. Angiotensin receptor type 1 median ratio was 12.5 % and AT2-R one was 10%. Figure 2 shows that AT1-R was overexpressed by Fuhrman’s 4 RCCC compared with other grade tumours (P<0.001; panel A). Angiotensin type-2 receptor was also overexpressed by Fuhrman’s 4 RCCC (P<0.001; panel B).

Western blot

Frozen tumours were included in the WB experiments to confirm IHC results by another semi-quantitative method (Figure 3). A total of 47 frozen samples (2 Fuhrman’s grade 1, 15 grade 2, 19 grade 3 and 11 grade 4) containing tumour tissue alone were analysed. Samples with significant proportion of non-tumour tissue or fibrosis or necrosis (more than 10%) were excluded. The AT1-R was overexpressed by the higher Fuhrman’s grade tumours as shown in Figure 3 (P<0.001; panel A). A total of 51 samples were included to quantify AT2-R by WB (3 Fuhrman’s grade 1, 18 grade 2, 20 grade 3 and 10 grade 4). Angiotensin type-2 receptor was also significantly increased in high Fuhrman’s grade tumours (P = 0.001; panel B).

qRT–PCR

By RT–PCR, AT1-R expression was analysed on 55 samples (3 grade 1 tumours, 17 grade 2, 17 grade 3 and 18 grade 4).
It was significantly decreased according to the Fuhrman’s grade (Figure 4 - panel A, \( P < 0.001 \)). However, on the 44 tumours suitable for analysis (2 grade 1, 12 grade 2, 15 grade 3 and 15 grade 4), AT2-R mRNA was not differentially expressed according to Fuhrman’s grade (panel B; \( P = 0.118 \), NS).

**Survival, univariate and multivariate analyses**

Progression-free survival was assessed by the Kaplan–Meier method and compared by log-rank test according to the level of AT1-R and AT2-R (\( \leq \) or \( > \) median expression determined by IHC).
Translational Therapeutics

Figure 5 shows that PFS was better when AT1-R was expressed below 12.5% (median) by IHC ($P = 0.006$; panel A) and AT2-R below 10% (median) ($P = 0.001$; panel B). Univariate and multivariate analysis results are presented in Table 1 for AT1-R and in Table 2 for AT2-R. By univariate analysis, PFS correlated with AT1-R ($P = 0.001$), as well as stage (T1/2 vs T3/4, $P < 0.001$), nodal invasion ($P < 0.001$), distant metastasis ($P < 0.001$), tumor size ($< or > 7 cm$, $P = 0.001$), Fuhrman’s grade (F1/2 vs F3/4 $P < 0.001$) but not ECOG stage ($P = 0.239$). By multivariate analysis, AT1-R did not correlate with PFS (NS) on the contrary to tumour stage ($P < 0.001$), Fuhrman’s grade ($P = 0.044$), nodal invasion ($P = 0.003$) and ECOG stage ($P = 0.005$). For AT2-R, univariate analysis showed that PFS correlated with AT2-R ($P = 0.001$), as well as tumour stage (T1/2 vs T3/4, $P < 0.001$), nodal invasion ($P = 0.002$), distant metastasis ($P < 0.001$), tumor size ($< or > 7 cm$, $P = 0.001$), Fuhrman’s grade (F1/2 vs F3/4 $P < 0.001$) but not ECOG stage (0.253). By multivariate analysis, AT2-R was still correlated with PFS ($P = 0.006$) as tumour stage ($P < 0.001$).

**DISCUSSION**

Our study shows that both AT1-R and AT2-R protein expression correlate with RCCC aggressiveness and PFS. This relationship

---

**Table 1** Variables associated with progression-free survival in univariate analysis and with Cox proportional hazards regression model for AT1-R expressed by IHC

| Variables (No. of patients) | Percentage of progression | P (univariate analysis) | Multivariate analysis hazard ratios (95% CI) | P |
|-----------------------------|---------------------------|-------------------------|-------------------------------------------|---|
| Stage                       |                           |                         |                                           |   |
| T1/2                        | (45) 11.1 %               | <0.001                  | 9.841                                    | <0.001 |
| T3/4                        | (39) 61.5 %               |                         |                                           |   |
| Nodal invasion              |                           |                         |                                           |   |
| No                         | (73) 28.7 %               | <0.001                  | 4.245                                    | 0.003 |
| Yes                        | (11) 72.7 %               |                         |                                           |   |
| Distant metastasis         |                           |                         |                                           |   |
| No                         | (47) 22.6 %               | <0.001                  | NS                                       |   |
| Yes                        | (37) 68.2 %               |                         |                                           |   |
| Tumor size                 |                           |                         |                                           |   |
| ≤7 cm                      | (44) 15.9 %               | <0.001                  | NS                                       |   |
| >7 cm                      | (40) 55 %                 |                         |                                           |   |
| Fuhrman’s grade            |                           |                         |                                           |   |
| 1+2                        | (35) 8.5 %                | <0.001                  | 3.688                                    | 0.044 |
| 3+4                        | (49) 53.0 %               |                         |                                           |   |
| AT1R ≤ or > 12.5%          |                           |                         |                                           |   |
| ≤12.5%                     | (41) 25 %                 | <0.001                  | NS                                       |   |
| >12.5%                     | (43) 44.7 %               |                         |                                           |   |
| ECOG                        |                           |                         |                                           |   |
| 0                          | (56) 28.5 %               | 0.029                   | 3.487                                    | 0.005 |
| 1 or more                  | (28) 46.4 %               |                         |                                           |   |

Abbreviations: AT1R = angiotensin type 1 receptor; CI = confidence interval; ECOG = eastern cooperative oncology group performance status.

**Table 2** Variables associated with progression-free survival in univariate analysis and with Cox proportional hazards regression model for AT2-R expressed by IHC

| Variables (No. of patients) | Percentage of progression | P (univariate analysis) | Multivariate analysis hazard ratios (95% CI) | P |
|-----------------------------|---------------------------|-------------------------|-------------------------------------------|---|
| Stage                       |                           |                         |                                           |   |
| T1/2                        | (45) 11.1 %               | <0.001                  | 14.297                                   | <0.001 |
| T3/4                        | (39) 61.5 %               |                         |                                           |   |
| Nodal invasion              |                           |                         |                                           |   |
| No                         | (73) 28.7 %               | <0.001                  | NS                                       |   |
| Yes                        | (11) 72.7 %               |                         |                                           |   |
| Distant metastasis         |                           |                         |                                           |   |
| No                         | (47) 22.6 %               | <0.001                  | NS                                       |   |
| Yes                        | (37) 68.2 %               |                         |                                           |   |
| Tumor size                 |                           |                         |                                           |   |
| ≤7 cm                      | (44) 15.9 %               | <0.001                  | NS                                       |   |
| >7 cm                      | (40) 55 %                 |                         |                                           |   |
| Fuhrman’s grade            |                           |                         |                                           |   |
| 1+2                        | (35) 8.5 %                | <0.001                  | NS                                       |   |
| 3+4                        | (49) 53.0 %               |                         |                                           |   |
| AT2R ≤ or > 10%            |                           |                         |                                           |   |
| ≤10%                       | (42) 17.5 %               | <0.001                  | NS                                       |   |
| >10%                       | (42) 47.2 %               |                         |                                           |   |
| ECOG                        |                           |                         |                                           |   |
| 0                          | (56) 28.5 %               | 0.025                   | 1.021                                    | 0.006 |
| 1 or more                  | (28) 46.4 %               |                         |                                           |   |

Abbreviations: AT1R = angiotensin type 1 receptor; CI = confidence interval; ECOG = eastern cooperative oncology group performance status.
suggests a role for these two receptors in regulating tumour growth and/or neoangiogenesis and a potential therapeutic effect of receptor antagonists.

AT1-R overexpression has already been described in other cancers but not previously for RCCC. This correlation might be because of a direct effect of ATII on tumour cells. Indeed, ATII through AT1-R can activate tumour cell proliferation through at least two simultaneous mechanisms: PI3-kinase/Akt pathway (Zhao et al, 2010) and EGFR (epithelial growth factor receptor) trans-activation (Fujiiya et al, 2001; Greco et al, 2003; Uemura et al, 2003). Secondly, ATII through AT1-R can induce an increased expression and production in vascular endothelial growth factor (VEGF) inducing neo-angiogenesis (Arafat et al, 2007; Kosaka et al, 2010). Induction might be triggered by stabilisation of hypoxia inducible factor-1α (HIF1α), as shown in prostate cancer model (Richard et al, 2000; Ino et al, 2006; Kosaka et al, 2010). Positive correlation between AT1-R expression and VEGF production has been shown in ovarian cancer, in vivo. Moreover, ATII through AT1-R reduces tumour cell adhesion although reducing invasion of the basement membrane (Puddefoot et al, 2006). Lastly, in a mouse model of gastric cancer AT1-R could trigger lymphangiogenesis (Wang et al, 2008).

AT2-R is overexpressed by some cancers such as gastric cancers (Rcken et al, 2007) though its role in carcinogenesis remains controversial. Under physiological conditions, AT2-R has anti-proliferative properties (Fujiiya et al, 2001), whereas during carcinogenesis, AT2-R can induce an invasive phenotype, for example in gastric cancer (Carl-McGrath et al, 2007), or prevent cell proliferation (Bose et al, 2009). However, AT2-R has been shown to counteract the effects of ATII mediated by AT1-R, and might be upregulated upon prolonged ATII stimulation (Noet and Nahmias, 2000). High expression of AT2-R in RCCC could be either a consequence of AT1-R overexpression or of the high circulating level of ATII and/or may have specific angiogenesis effects as in gastric cancer. Even more, in kidney, AT2-R can physiologically induce tubular cell proliferation during development or after kidney injury (Cao et al, 2000). As RCCC develops from tubular cells, AT2-R overexpression may be one of the mechanisms by which tubular cell proliferation develops into carcinogenesis. The strong correlation between tumour aggressiveness, PFS and AT2-R expression in our study indeed supports the hypothesis for a proliferative effect of AT2-R in RCCC, more than in other type of cancers. Specific in vitro studies, using anti AT1-R and/or AT2-R inhibitors on RCCC-cultured cells will help to illuminate the role(s) of AT2-R in renal carcinogenesis.

In our ex vivo study, dissociation between AT1-R and AT2-R protein expression and RNA synthesis was also observed. As the staining of both receptors was mainly expressed by tumour cells as detected by IHC, and because the tumour nature of tissue analysed was controlled, we suggest that AT1-R and AT2-R mRNA amplified were indeed synthesised by tumour cells. We also suggest that post-transcriptional or post-translational mechanisms, never described in other type of cancer, might be involved in RCCC. The underlying mechanisms of receptor synthesis, internalisation, sequencing and inactivation are incompletely understood (Areschohorst et al, 1999).

The correlation between RAS and RCCC opens new potential therapeutic strategies in RCCC. Angiotensin-receptor blockers and ACEI are highly prescribed and well tolerated anti-hypertensive therapies. Large epidemiological studies suggest potential protective effects against cancer risk even if results remain controversial (Lever et al, 1998; Friis et al, 2001). Angiotensin-receptor blockers and ACEI could act on tumour progression by two different mechanisms: inhibition of cancer proliferation and/or inhibition of neoangiascularization. In experimental studies on different cancer types, ARB or ACEI showed anti-proliferative effects: in breast cancer cells (Puddefoot et al, 2006; Rhodes et al, 2009) in human melanoma xenograft model (de Groot-Besseling et al, 2004), in murine hepatocellular carcinoma (Noguchi et al, 2003), in colorectal cancer liver metastases (Neo et al, 2007), on pancreatic cancer cells (Arafat et al, 2007) or on lung metastases of mouse RCCC (Miyajima et al, 2002). Inhibition of tumour growth involves the decreased expression of VEGF. It has been shown for pancreatic cancer (Arafat et al, 2007; Noguchi et al, 2009) and for prostate cancer (Kosaka et al, 2010). The inhibition of endothelial cell tubular formation (Yoshiji et al, 2005) and/or apoptosis of endothelial or tumour cells (De la Iglesia Inigo et al, 2009) were also described. In a recent model of murine melanoma graft, ARB-induced tumour growth decrease by low microvascular density, and the decrease of some angiogenic mediators such as VEGF-1 and VEGF-2 (Otake et al, 2009). In addition, in animal models, ARB or ACEI enhance the effect of usual chemotherapies: in murine hepatocarcinoma in association to interferon- (Noguchi et al, 2003), in mouse bladder cancer combined with cis-platin by further suppressing angiogenesis (Kosugi et al, 2009), by enhancing effects of radiation (Ohnuma et al, 2009), or in addition with K2 vitamin in hepatocellular carcinoma in rats (Yoshiji et al, 2006).

Furthermore, few recent clinical trials reported that ARB could improve cancer prognosis when used in association with standard chemotherapies. In a report of three cases of metastatic RCCC, ARB was associated with cinetidine and cyclo-oxygenase 2 inhibitors allowing prolonged partial remission (Tatokoro et al, 2008). In a retrospective cohort study on advanced non-small-cell lung cancer, ARB or ACEI were statistically associated with longer patient survival when used with first-line platinum-based chemotherapy (Wilson et al, 2009). One pharmacological AT2-R blocker (PD123319) has been used with controversial results. It can facilitate tumourogenesis by Pax2 activation and resulted in prostatic cancer-cell proliferation (Bose et al, 2009). In a gastric cancer model, the same AT2-R blocker induced cell proliferation and cell viability, but inhibited cell invasion (Carl-McGrath et al, 2007). In recent work on pancreatic cancer cells, it also enhanced production of the inflammatory mediator MCP-1, which promotes tumour invasion (Chehl et al, 2009). According to this tissue specificity of AT2-R expression and AT2-R blocker effect, overexpression of AT2-R in the RCCC may suggest a different role of AT2-R and in consequence, different actions of its blocker.

For RCCC, 40% of the patients develop distant metastases with poor prognosis. As RCCC are highly vascularises cancers, with high secretion of VEGF (Rioux-Leclercq et al, 2007), recent therapies are focused on anti-angiogenic drugs (Rini, 2009): anti-VEGF antibody (bevacizumab) (Rini et al, 2008) or tyrosine kinase inhibitors (Sunitinib, sorafenib) (Motzer et al, 2007; Negrier et al, 2009). These drugs already significantly increased patient survival but PFS is still counted in months (Motzer et al, 2007). Our study demonstrates that AT1-R and AT2-R are overexpressed in RCCC, and that this overexpression correlates with tumour aggressiveness and PFS. In consequence, AT1-R and AT2-R can be used as new prognosis factors for RCCC but ARB and ACEI can also be suggested as new adjuvant pathway for RCCC therapy. Indeed, these results, in addition to already-published experimental and clinical data on other cancer types, suggest that blocking RAS might be a way to decrease RCCC growth, neovascularization and metastasis dissemination. Experimental in vitro and in vivo studies with ARB and ACEI, in addition to antiangiogenic therapies, are the following steps to confirm our hypothesis.

CONCLUSION

Our study first report that AT1-R and AT2-R protein expression can be used as new prognosis factors in RCCC, strongly related to tumour aggressiveness and worse PFS. These results support the hypothesis that ARB and ACEI could represent interesting adjuvant treatments in metastatic RCCC.
ACKNOWLEDGEMENTS
The authors would like to thank Dr Stuart T Fraser for his help in revising English language, and INCa (Institut National du Cancer), Brittany region, the scientific committee of the Rennes medical faculty and the French 'Sociétée de Néphrologie' for their fundings.

REFERENCES

Arafat HA, Gong Q, Chipitsyna G, Sizvi A, Saa CT, Yeo CJ (2007) Antihypertensives as novel anionoeplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 204: 996 – 1005; discussion 1005 – 1006

Arendshorst WJ, Brannstrom K, Ruan X (1999) Actions of angiotensin II on the renal microcirculation. J Am Soc Nephrol 10(Suppl 11): SI49 – SI61

Arrieta O, Pineda-Olvera B, Gomez-Casares MT, Lemes Castellano A (2008) Potential role of Renin-Angiotensin-system for tumor angiogenesis. Angiotensin II receptor subtypes in the human renal cortex and renal proximal tubular cells. Kidney Int 58: 2437 – 2451

Arrieta O, Pineda-Olvera B, Guevara-Salazar P, Hernandez-Pedro N, Bose SK, Gibson W, Giri S, Nath N, Donald CD (2009) Angiotensin II binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation in breast cancer cells. J Cell Physiol 223: 29 – 38

Asano T, Ohnuma Y, Toda M, Fujita M, Hosono K, Suzuki T, Ogawa Y, Amano H, Kitasato H, Hayakawa K, Majima M (2009) Blockade of an angiotensin II type 1 receptor enhances effects of radiation on tumour growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother 63: 136 – 145

Bose SK, Gibson W, Giri S, Nath N, Donald CD (2009) Angiotensin II up-regulates PAX2 oncogene expression and activity in prostate cancer via the angiotensin II type I receptor. Prostate 69: 1334 – 1342

Cao Z, Kelly DJ, Cox A, Casey D, Forbes JM, Martinello P, Dean R, Gilbert RE, Cooper ME (2000) Angiotensin II type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int 58: 699 – 705

Carl-McGrath S, Ebert MP, Lendeckel U, Rocken C (2007) Expression of the local Angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol Ther 6(8): 1218 – 1226

Chatterjee PK, Weerackody RP, Mistry SK, Hawskworth GM, McClay JS (1997) Selective antagonism of the AT1 receptor inhibitors angiotensin II stimulated DNA and protein synthesis in primary cultures of human proximal tubular cells. Kidney Int 52: 699 – 705

Chehl N, Gong Q, Chipitsyna G, Aziz T, Yeo CJ, Arafat HA (2009) Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells. J Gastrointest Surg 13(12): 2189 – 2200

de Groot-Besseling RR, Ruers TJ, van Kraats AA, Zaal KM, Ruiter DJ, de Waal RM, Westphal JR (2004) Anti-tumour activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 112: 329 – 334

De la Iglesia Inigo S, Lopez-Jorge CE, Gomez-Casares MT, Melo F, Arraya FL, Carmona-Lopez P, Llorca J (2006) Angiotensin II type 1 antagonist inhibits mural angiogenesis in in situ hybridization. Nephron 98: 25 – 34

De la Iglesia Inigo S, Lopez-Jorge CE, Gomez-Casares MT, Melo F, Arraya FL, Carmona-Lopez P, Llorca J (2006) Angiotensin II type 1 antagonist inhibits mural angiogenesis in in situ hybridization. Nephron 98: 25 – 34

Dolley-Hitze T et al (2006) Angiotensin-2 receptors in renal carcinoma. J Urol 175: 208 – 213

Durante-Mangoni ER, Siteman CM, Jordan MA, Smith FA, Earle RC, Seigler HF (2001) Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma. Cancer Res 61: 1218 – 1226

Ehara F, Kawajiri T, Hasegawa M, Ikeda N, Nakao H, Tsuchiya K, Arai H, Takase K, Yamaguchi S, Nakano Y (2001) Expression of angiotensin II type I and AT2 receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor-1 in mouse melanoma cells. J Cell Physiol 188: 399 – 407

Ehrnstrom D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R, Wulf C (2008) Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 109: 418 – 425

Eno J, Kishida K, Kajiya H, Yamamoto E, Nagasaka T, Nawa A, Nomura S, Kikikawa F (2006) Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer 94: 552 – 560

Figlin RA, Mancini CW, Oudard S, Negrier S, Jager E, Porta C, McDermott D, Moore MJ, Bellmunt J, Anderson S, Fizazi K, Higano CST, Ohnuma Y, Toda M, Fujita M, Hosono K, Suzuki T, Ogawa Y, Amano H, Kitasato H, Hayakawa K, Majima M (2009) Blockade of an angiotensin II type 1 receptor enhances effects of radiation on tumour growth and tumor-associated angiogenesis by reducing vascular endothelial growth factor expression. Biomed Pharmacother 63: 136 – 145
Angiotensin-2 receptors in renal carcinoma

T Dolley-Hitze et al.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. *Am J Clin Oncol* 5: 649 – 655

Otake AH, Mattar AL, Freitas HC, Machado CM, Nonogaki S, Fujihara CK, Zatz R, Chammas R (2009) Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. *Cancer Chemother Pharmacol* 66(4): 79 – 87

Puddefoot J, Udeozo UK, Barker S, Vinson GP (2006) The role of angiotensin II in the regulation of breast cancer cell adhesion and invasion. *Endocr Relat Cancer* 13: 895 – 903

Rhodes DR, Ateeq B, Cao Q, Tomlins SA, Mehra R, Laxman B, Kalyana-Sundaram S, Lonigro RJ, Helgeson BE, Bhojani MS, Rehemtulla A, Kleer CG, Hayes DF, Lucas PC, Varambally S, Chinnaiyan AM (2009) AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. *Proc Natl Acad Sci USA* 106: 10284 – 10289

Richard DE, Berra E, Pouyssegur J (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. *J Biol Chem* 275: 26765 – 26771

Rini BI (2009) Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. *Cancer* 115: 2306 – 2312

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czyzakowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J Clin Oncol* 26: 5422 – 5428

Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, Richard DE, Berra E, Pouyssegur J (2000) Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. *J Biol Chem* 275: 26765 – 26771

Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czyzakowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. *J Clin Oncol* 26: 5422 – 5428

Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, Epstein JL, Patard JJ (2007) Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. *Hum Pathol* 38: 1489 – 1495

Rocken C, Kohl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S, Ebert MP (2007) The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. *Cancer Epidemiol Biomarkers Prev* 16: 1206 – 1212

Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T (1995) The role of angiotensin type-1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumour invasion, angiogenesis, and peritoneal dissemination. *Clin Cancer Res* 11: 2686 – 2694

Takeda M, Kondo S (2001) Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. *Am J Pathol* 158: 1633 – 1637

Tamura M, Yan H, Zagarra-Moro O, Edl J, Oursler S, Chard-Bergstrom C, Andrews G, Kanehira T, Takekoshi S, Mernaugh R (2000) Specific single chain variable fragment (ScFv) antibodies to angiotensin II AT(2) receptor: evaluation of the angiotensin II receptor expression in normal and tumor-bearing mouse lung. *J Mol Histol* 39: 351 – 358

Tatokoro M, Fujii Y, Kawakami S, Fuku N, Komai Y, Saito K, Koga F, Morimoto S, Fuku i, Kihara K (2008) Favorable response to combination treatment of cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin system inhibitor in metastatic renal cell carcinoma: Report of three cases. *Int J Urol* 15: 848 – 850

Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y (2003) Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. *Mol Cancer Ther* 2: 1139 – 1147

Wang L, Cai SR, Zhang CH, He YL, Zhan WH, Wu H, Peng J (2008) Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model. *Chin Med J (Engl)* 121: 2167 – 2171

Weerackody RP, Chatterjee PK, Mistry SK, McLaren J, Hawksworth GM, McIay JS (1997) Selective antagonism of the AT1 receptor inhibits the effect of angiotensin II on DNA and protein synthesis of rat proximal tubular cells. *Exp Nephrol* 5: 253 – 262

Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. *J Cancer Res Clin Oncol* 135(10): 1429 – 1435

Yoshiji H, Kuriyama S, Fukui H (2002) Perindopril: possible use in cancer therapy. *Anticancer Drugs* 13: 221 – 228

Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namissaki T, Kitade M, Yamazaki M, Akahane T, Asada K, Tsujimoto T, Uemura M, Fukui H (2006) Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. *Oncl Rep* 15: 155 – 159

Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namissaki T, Kitade M, Yamazaki M, Akahane T, Asada K, Tsujimoto T, Uemura M, Fukui (2006) Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. *Oncl Rep* 15: 155 – 159

Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S (2010) Angiotensin II/angiotensin II type 1 receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase/Akt pathway. *J Cell Physiol* 225(1): 168 – 173